Pfizer (PFIZER) Stock Overview
Engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
PFIZER Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pfizer Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,168.00 |
| 52 Week High | ₹6,451.15 |
| 52 Week Low | ₹3,701.00 |
| Beta | 0.13 |
| 1 Month Change | -2.07% |
| 3 Month Change | -7.93% |
| 1 Year Change | -13.24% |
| 3 Year Change | 21.65% |
| 5 Year Change | 8.63% |
| Change since IPO | 266.92% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 28%
May 28
Pfizer (NSE:PFIZER) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
May 26Pfizer Limited's (NSE:PFIZER) Share Price Not Quite Adding Up
Mar 03Some Confidence Is Lacking In Pfizer Limited's (NSE:PFIZER) P/E
Nov 28We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt
Aug 31Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%
Aug 07Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)
May 25Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet
Feb 13Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price
Jan 17Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly
Mar 15A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)
Jul 20Pfizer (NSE:PFIZER) Could Easily Take On More Debt
Mar 29Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)
Feb 07These 4 Measures Indicate That Pfizer (NSE:PFIZER) Is Using Debt Safely
Sep 23This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation
Aug 12Shareholder Returns
| PFIZER | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -9.0% | -0.9% | -1.5% |
| 1Y | -13.2% | -5.3% | -7.1% |
Return vs Industry: PFIZER underperformed the Indian Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: PFIZER underperformed the Indian Market which returned -7.1% over the past year.
Price Volatility
| PFIZER volatility | |
|---|---|
| PFIZER Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 7.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: PFIZER has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: PFIZER's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 1,598 | Meenakshi Nevatia | www.pfizerltd.co.in |
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes.
Pfizer Limited Fundamentals Summary
| PFIZER fundamental statistics | |
|---|---|
| Market cap | ₹236.42b |
| Earnings (TTM) | ₹8.09b |
| Revenue (TTM) | ₹23.22b |
Is PFIZER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFIZER income statement (TTM) | |
|---|---|
| Revenue | ₹23.22b |
| Cost of Revenue | ₹8.26b |
| Gross Profit | ₹14.95b |
| Other Expenses | ₹6.87b |
| Earnings | ₹8.09b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 14, 2025
| Earnings per share (EPS) | 176.76 |
| Gross Margin | 64.41% |
| Net Profit Margin | 34.83% |
| Debt/Equity Ratio | 2.6% |
How did PFIZER perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 18:46 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |